Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690178 | 1.00 | AR (0.45) | ARPARP1CYP1A2CHEK1TYMS | |
| SCHEMBL13145722 | 0.80 | AR (0.43) | ARPARP1CHEK1TYMSROCK2 | |
| SCHEMBL26615075 | 0.79 | AR (0.45) | ARPARP1TYMSROCK2NAMPT | |
| SCHEMBL764379 | 0.79 | AR (0.45) | ARPARP1TYMSROCK2NAMPT | |
| SCHEMBL13180318 | 0.79 | AR (0.52) | ARPARP1 | |
| SCHEMBL30319337 | 0.78 | AR (0.41) | ARPARP1CYP1A2L3MBTL1ROCK2 | |
| SCHEMBL4234184 | 0.74 | ADORA2A (0.41) | ARCYP1A2CHEK1 | |
| SCHEMBL30319361 | 0.74 | AR (0.42) | ARPARP1CYP1A2L3MBTL1ROCK2 | |
| SCHEMBL555280 | 0.74 | ATM (0.57) | ARPARP1CYP1A2ATMNPSR1 | |
| SCHEMBL14127343 | 0.73 | RAPGEF4 (0.35) | ARPARP1CYP1A2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, CUL1, PSMB10 | AR 1421/4885PARP1 1721/4885CYP1A2 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.